

# Myriam Calle Rubio

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4258381/publications.pdf>

Version: 2024-02-01

123  
papers

5,133  
citations

101543

36  
h-index

95266

68  
g-index

148  
all docs

148  
docs citations

148  
times ranked

3914  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effectiveness and Safety of Inhaled Antibiotics in Patients With Chronic Obstructive Pulmonary Disease. A Multicentre Observational Study. Archivos De Bronconeumología, 2022, 58, 11-21.	0.8	25
2	[Translated article] Spanish COPD guidelines (GesEPOC) 2021: Updated pharmacological treatment of stable COPD. Archivos De Bronconeumología, 2022, 58, T69-T81.	0.8	27
3	[Translated article] Spanish COPD Guideline (GesEPOC) Update: Comorbidities, Self-Management and Palliative Care. Archivos De Bronconeumología, 2022, 58, T334-T344.	0.8	4
4	[Translated article] Spanish COPD Guidelines (GesEPOC) 2021 Update. Diagnosis and Treatment of COPD Exacerbation Syndrome. Archivos De Bronconeumología, 2022, 58, T159-T170.	0.8	16
5	Long-term Outcomes and Recovery of Patients who Survived COVID-19: LUNG INJURY COVID-19 Study. Open Forum Infectious Diseases, 2022, 9, ofac098.	0.9	11
6	[Translated article] Spanish COPD Guidelines (GesEPOC 2021): Non-pharmacological Treatment Update. Archivos De Bronconeumología, 2022, 58, T345-T351.	0.8	8
7	Testing for Vitamin D in High-Risk COPD in Outpatient Clinics in Spain: A Cross-Sectional Analysis of the VITADEPOC Study. Journal of Clinical Medicine, 2022, 11, 1347.	2.4	2
8	Determinants in the Underdiagnosis of COPD in Spain—CONOCEPOC Study. Journal of Clinical Medicine, 2022, 11, 2670.	2.4	2
9	Results of a Diagnostic Procedure Based on Multiplex Technology on Dried Blood Spots and Buccal Swabs for Subjects With Suspected Alpha1 Antitrypsin Deficiency. Archivos De Bronconeumología, 2021, 57, 42-50.	0.8	14
10	GesEPOC 2021: un paso más en la personalización del tratamiento de la EPOC. Archivos De Bronconeumología, 2021, 57, 9-10.	0.8	21
11	Assessing the Usefulness of the Prevexair Smartphone Application in the Follow-Up High-Risk Patients with COPD. International Journal of COPD, 2021, Volume 16, 53-65.	2.3	2
12	COPD Clinical Control: predictors and long-term follow-up of the CHAIN cohort. Respiratory Research, 2021, 22, 36.	3.6	2
13	Utility of Transient Elastography for the Screening of Liver Disease in Patients with Alpha1-Antitrypsin Deficiency. Journal of Clinical Medicine, 2021, 10, 1724.	2.4	10
14	Spanish COPD guidelines (GesEPOC) 2021: Updated pharmacological treatment of stable COPD. Archivos De Bronconeumología, 2021, 58, T69-T69.	0.8	13
15	Noninvasive electrical stimulation of oropharyngeal muscles in obstructive sleep apnea. Expert Review of Respiratory Medicine, 2021, 15, 1-14.	2.5	3
16	Natural Course of the Diffusing Capacity of the Lungs for Carbon Monoxide in COPD. Chest, 2021, 160, 481-490.	0.8	16
17	Consenso sobre el diagnóstico, tratamiento y seguimiento de la EPOC: Grupo de trabajo EPOC Forum. Archivos De Bronconeumología, 2021, 57, 596-599.	0.8	2
18	Results of a Diagnostic Procedure Based on Multiplex Technology on Dried Blood Spots and Buccal Swabs for Subjects With Suspected Alpha1 Antitrypsin Deficiency. Archivos De Bronconeumología, 2021, 57, 42-50.	0.8	7

#	ARTICLE	IF	CITATIONS
19	Off-label use of inhaled bronchodilators in hospitalised patients in Spain: a multicentre observational study. <i>European Journal of Hospital Pharmacy</i> , 2021, 28, e23-e28.	1.1	3
20	Knowledge of chronic obstructive pulmonary disease, presence of chronic respiratory symptoms and use of spirometry among the Spanish population: CONOCEPOC 2019 study. <i>Archivos De Bronconeumologia</i> , 2021, 57, 741-749.	0.8	6
21	Spanish COPD Guidelines (GesEPOC) 2021 Update Diagnosis and Treatment of COPD Exacerbation Syndrome. <i>Archivos De Bronconeumologia</i> , 2021, , .	0.8	3
22	Conocimiento de la enfermedad pulmonar obstructiva cr�nica, presencia de s�ntomas respiratorios cr�nicos y uso de la espirometr�a en la poblaci�n espa�ola: estudio CONOCEPOC 2019. <i>Archivos De Bronconeumologia</i> , 2021, 57, 741-749.	0.8	7
23	Consensus document on the diagnosis and treatment of chronic bronchial infection in chronic obstructive pulmonary disease. <i>Archivos De Bronconeumologia</i> , 2020, 56, 651-664.	0.8	20
24	Prevalence of modifiable factors limiting treatment efficacy of poorly controlled asthma patients: EFIMERA observational study. <i>Npj Primary Care Respiratory Medicine</i> , 2020, 30, 33.	2.6	3
25	&lt;p&gt;A Proposed Approach to Chronic Airway Disease (CAD) Using Therapeutic Goals and Treatable Traits: A Look to the Future&lt;/p&gt;. <i>International Journal of COPD</i> , 2020, Volume 15, 2091-2100.	2.3	27
26	The Importance of Reference Centers and Registries for Rare Diseases: The Example of Alpha-1 Antitrypsin Deficiency. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2020, 17, 346-354.	1.6	14
27	Compliance and Utility of a Smartphone App for the Detection of Exacerbations in Patients With Chronic Obstructive Pulmonary Disease: Cohort Study. <i>JMIR MHealth and UHealth</i> , 2020, 8, e15699.	3.7	16
28	Development and Preliminary Evaluation of the Effects of an mHealth Web-Based Platform (HappyAir) on Adherence to a Maintenance Program After Pulmonary Rehabilitation in Patients With Chronic Obstructive Pulmonary Disease: Randomized Controlled Trial. <i>JMIR MHealth and UHealth</i> , 2020, 8, e18465.	3.7	31
29	KaLinix� in the treatment of Obstructive Sleep Apnea-Hypopnea syndrome (OSAHS). , 2020, , .		0
30	Are there Clinically Relevant Benefits in a Structured Program of Physical Activity in COPD? Activepoc Study. , 2020, , .		0
31	Benefits of Measured Isotiming in Constant Cardiopulmonary Exercise Testing in a Structured Physical Activity Program. , 2020, , .		0
32	Diagnostic efficacy of the KaLinix� intelligent medical device for diagnosis of obstructive sleep apnea and hypopnea syndrome. , 2020, , .		0
33	Important Benefits of EBUS-TBNA in Assessing PD-L1 Expression in NSCLC. , 2020, , .		0
34	Benralizumab for the Prevention of COPD Exacerbations. <i>New England Journal of Medicine</i> , 2019, 381, 1023-1034.	27.0	180
35	Assessing the clinical practice in specialized outpatient clinics for chronic obstructive pulmonary disease: Analysis of the EPOCONSUL clinical audit. <i>PLoS ONE</i> , 2019, 14, e0211732.	2.5	4
36	Asthma patient satisfaction with different dry powder inhalers. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 133-138.	2.5	15

#	ARTICLE	IF	CITATIONS
37	Clinical control of COPD according to outpatient respiratory clinics: general versus specialized COPD. , 2019, , .		0
38	Pro-inflammatory / anti-inflammatory capacity of lymphocyte cells in COPD. , 2019, , .		0
39	Clinical characteristics of COPD and resources in general and specialized COPD outpatient respiratory clinics. , 2019, , .		0
40	Medical Care According to Risk Level and Adaptation to Spanish COPD Guidelines (GesEPOC): The Epoconsul Study. Archivos De Bronconeumologia, 2018, 54, 270-279.	0.8	11
41	Atención médica según el nivel de riesgo y su adecuación a las recomendaciones de la guía española de la enfermedad pulmonar obstructiva crónica (EPOC) (GesEPOC): Estudio EPOCONSUL. Archivos De Bronconeumologia, 2018, 54, 270-279.	0.8	38
42	Changes and Clinical Consequences of Smoking Cessation in Patients With COPD. Chest, 2018, 154, 274-285.	0.8	6
43	The importance of symptoms in the longitudinal variability of clusters in COPD patients: A validation study. Respirology, 2018, 23, 485-491.	2.3	9
44	Impact of patient satisfaction with his or her inhaler on adherence and asthma control. Allergy and Asthma Proceedings, 2018, 39, 437-444.	2.2	39
45	For the Patient. Allergy and Asthma Proceedings, 2018, 39, 472-472.	2.2	0
46	Evaluating the impact of morning symptoms in COPD using the Capacity of Daily Living during the Morning (CDLM) questionnaire. International Journal of COPD, 2018, Volume 13, 3837-3844.	2.3	3
47	Characteristics of COPD Patients Managed in Respiratory Medicine Departments in Spain, According to GOLD Groups and GesEPOC Clinical Phenotypes. Archivos De Bronconeumologia, 2018, 54, 559-567.	0.8	3
48	Testing for alpha-1 antitrypsin in COPD in outpatient respiratory clinics in Spain: A multilevel, cross-sectional analysis of the EPOCONSUL study. PLoS ONE, 2018, 13, e0198777.	2.5	14
49	Determinants of medical prescriptions for COPD care: an analysis of the EPOCONSUL clinical audit. International Journal of COPD, 2018, Volume 13, 2279-2288.	2.3	13
50	Características de los pacientes con EPOC tratados en neumología en España según grupos GOLD y fenotipos clínicos GesEPOC. Archivos De Bronconeumologia, 2018, 54, 559-567.	0.8	22
51	Factors associated with testing of COPD patients for serum AAT levels to detect cases of AATD. The EPOCONSUL study.. , 2018, , .		0
52	The Capacity of Daily Living during the Morning (CDLM) questionnaire: Evaluating the impact of morning symptoms in COPD. , 2018, , .		0
53	Algorithm for identification of asthma-COPD overlap: consensus between the Spanish COPD and asthma guidelines. European Respiratory Journal, 2017, 49, 1700068.	6.7	75
54	Spanish COPD Guidelines (GesEPOC) 2017. Pharmacological Treatment of Stable Chronic Obstructive Pulmonary Disease. Archivos De Bronconeumologia, 2017, 53, 324-335.	0.8	30

#	ARTICLE	IF	CITATIONS
55	Consensus on the Asthma-COPD Overlap (ACO) Between the Spanish COPD Guidelines (GesEPOC) and the Spanish Guidelines on the Management of Asthma (GEMA). Archivos De Bronconeumologia, 2017, 53, 443-449.	0.8	31
56	Consenso sobre el solapamiento de asma y EPOC (ACO) entre la Gua espaola de la EPOC (GesEPOC) y la Gua Espaola para el Manejo del Asma (GEMA). Archivos De Bronconeumologia, 2017, 53, 443-449.	0.8	102
57	Gua espaola de la enfermedad pulmonar obstructiva crnica (GesEPOC) 2017. Tratamiento farmacolgico en fase estable. Archivos De Bronconeumologia, 2017, 53, 324-335.	0.8	365
58	Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. European Respiratory Journal, 2017, 50, 1701162.	6.7	122
59	The variability of respiratory symptoms and associated factors in COPD. Respiratory Medicine, 2017, 129, 165-172.	2.9	24
60	Variability in adherence to clinical practice guidelines and recommendations in COPD outpatients: a multi-level, cross-sectional analysis of the EPOCONSUL study. Respiratory Research, 2017, 18, 200.	3.6	14
61	Identification and distribution of COPD phenotypes in clinical practice according to Spanish COPD Guidelines: the FENEPOC study. International Journal of COPD, 2017, Volume 12, 2373-2383.	2.3	48
62	A proposal for the withdrawal of inhaled corticosteroids in the clinical practice of chronic obstructive pulmonary disease. Respiratory Research, 2017, 18, 198.	3.6	38
63	Clinical audit of COPD in outpatient respiratory clinics in Spain: the EPOCONSUL study. International Journal of COPD, 2017, Volume 12, 417-426.	2.3	50
64	Prevalence and impact of depression on COPD. , 2017, , .		2
65	Control of asthma, adherence to inhaled therapy and usefulness of the Test of Adherence to Inhalers (TAI). Results of the ASCONA study. , 2017, , .		0
66	Impact of asthmatic patient satisfaction with the inhaler upon adherence, disease control and quality of life. Results of the ASCONA study. , 2017, , .		0
67	Factors associated with therapeutic compliance in COPD. , 2017, , .		3
68	Clinical audit of COPD in outpatient respiratory clinics in Spain. Effect of specialized COPD clinics and general respiratory clinics: the EPOCONSUL study. , 2017, , .		0
69	Use of health care resources in admissions of COPD exacerbations. , 2017, , .		0
70	Health literacy and health outcomes in chronic obstructive pulmonary disease. Respiratory Medicine, 2016, 115, 78-82.	2.9	62
71	Quality of Spirometric Data in Spain: The 3E Study. Archivos De Bronconeumologia, 2016, 52, 109.	0.8	0
72	Determinants of use of the bronchodilator test in primary and secondary care: results of a national survey in Spain. Clinical Respiratory Journal, 2016, 10, 217-222.	1.6	5

#	ARTICLE	IF	CITATIONS
73	Defining the Asthma-COPD Overlap Syndrome in a COPD Cohort. <i>Chest</i> , 2016, 149, 45-52.	0.8	227
74	Validation of the Spanish Version of the COPD-Q Questionnaire on COPD Knowledge. <i>Archivos De Bronconeumología</i> , 2016, 52, 12-16.	0.8	0
75	Calidad de los datos de las espirometrías en España: estudio 3E. <i>Archivos De Bronconeumología</i> , 2016, 52, 109.	0.8	0
76	Validación de la versión en español del cuestionario COPD-Q/EPOC-Q de conocimiento de la EPOC. <i>Archivos De Bronconeumología</i> , 2016, 52, 12-16.	0.8	10
77	Validation of the "Test of the Adherence to Inhalers"™ (TAI) for Asthma and COPD Patients. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2016, 29, 142-152.	1.4	146
78	Distribution and Outcomes of a Phenotype-Based Approach to Guide COPD Management: Results from the CHAIN Cohort. <i>PLoS ONE</i> , 2016, 11, e0160770.	2.5	57
79	Home pulmonary rehabilitation program in COPD : Conditioning factors. , 2016, , .		0
80	Differences in the use of spirometry between rural and urban primary care centers in Spain. <i>International Journal of COPD</i> , 2015, 10, 1633.	2.3	8
81	What pulmonologists think about the asthma&ndash;COPD overlap syndrome. <i>International Journal of COPD</i> , 2015, 10, 1321.	2.3	35
82	Oxygenation With a Single Portable Pulse-Dose Oxygen-Conserving Device and Combined Stationary and Portable Oxygen Delivery Devices in Subjects With COPD. <i>Respiratory Care</i> , 2015, 60, 382-387.	1.6	12
83	Differential Effect of Modified Medical Research Council Dyspnea, COPD Assessment Test, and Clinical COPD Questionnaire for Symptoms Evaluation Within the New GOLD Staging and Mortality in COPD. <i>Chest</i> , 2015, 148, 159-168.	0.8	96
84	Documento de consenso "Uso adecuado de los corticoides inhalados en la enfermedad pulmonar obstructiva crónica". <i>Archivos De Bronconeumología</i> , 2015, 51, 193-198.	0.8	35
85	Distribution of COPD phenotypes according to the Spanish COPD guidelines in clinical practice. , 2015, , .		0
86	New GOLD classification: longitudinal data on group assignment. <i>Respiratory Research</i> , 2014, 15, 3.	3.6	42
87	Multicentric study on the beta-blocker use and relation with exacerbations in COPD. <i>Respiratory Medicine</i> , 2014, 108, 737-744.	2.9	34
88	Inter-Regional Changes in the Performance and Interpretation of Spirometry in Spain: 3E Study. <i>Archivos De Bronconeumología</i> , 2014, 50, 475-483.	0.8	9
89	Guía española de la EPOC (GesEPOC). Actualización 2014. <i>Archivos De Bronconeumología</i> , 2014, 50, 1-16.	0.8	143
90	Cambios interregionales en la realización e interpretación de las espirometrías en España: estudio 3E. <i>Archivos De Bronconeumología</i> , 2014, 50, 475-483.	0.8	15

#	ARTICLE	IF	CITATIONS
91	Spanish Guideline for COPD (GesEPOC). Update 2014. Archivos De Bronconeumologia, 2014, 50, 1-16.	0.8	130
92	Clinical Application of the COPD Assessment Test. Chest, 2014, 146, 111-122.	0.8	20
93	Guidelines for the Management of Respiratory Complications in Patients With Neuromuscular Disease. Archivos De Bronconeumologia, 2013, 49, 306-313.	0.8	8
94	Formaci3n continuada en espirometr3as: una luz en el camino. Archivos De Bronconeumologia, 2013, 49, 369-370.	0.8	0
95	Continuing Education in Spirometry: A Light Along the Way. Archivos De Bronconeumologia, 2013, 49, 369-370.	0.8	0
96	Espirometr3a. Archivos De Bronconeumologia, 2013, 49, 388-401.	0.8	210
97	Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice. European Respiratory Journal, 2013, 41, 1252-1256.	6.7	162
98	A Comprehensive, National Survey of Spirometry in Spain. Chest, 2013, 144, 601-609.	0.8	33
99	A new approach to grading and treating COPD based on clinical phenotypes: summary of the Spanish COPD guidelines (GesEPOC). Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2013, 22, 117-121.	2.3	70
100	Reduction of severe exacerbations and hospitalization-derived costs in alpha-1-antitrypsin-deficient patients treated with alpha-1-antitrypsin augmentation therapy. Therapeutic Advances in Respiratory Disease, 2012, 6, 67-78.	2.6	44
101	Monitoring Breathing Rate at Home Allows Early Identification of COPD Exacerbations. Chest, 2012, 142, 1524-1529.	0.8	93
102	Clinical Phenotypes of COPD: Identification, Definition and Implications for Guidelines. Archivos De Bronconeumologia, 2012, 48, 86-98.	0.8	105
103	External Validation of the Recommendations of the Multidisciplinary Consensus About Inhaled Therapies. Archivos De Bronconeumologia, 2012, 48, 189-196.	0.8	5
104	Spanish COPD Guidelines (GesEPOC): Pharmacological Treatment of Stable COPD. Archivos De Bronconeumologia, 2012, 48, 247-257.	0.8	41
105	The General Public's Knowledge of Chronic Obstructive Pulmonary Disease and Its Determinants: Current Situation and Recent Changes. Archivos De Bronconeumologia, 2012, 48, 308-315.	0.8	31
106	Conocimientos de la poblaci3n general sobre la enfermedad pulmonar obstructiva cr3nica y sus determinantes: situaci3n actual y cambios recientes. Archivos De Bronconeumologia, 2012, 48, 308-315.	0.8	45
107	Chronic obstructive pulmonary disease History Assessment in Spain: una valoraci3n multidimensional de la enfermedad pulmonar obstructiva cr3nica. M3todo y organizaci3n del trabajo. Archivos De Bronconeumologia, 2012, 48, 453-459.	0.8	22
108	Physicians' Knowledge of Inhaler Devices and Inhalation Techniques Remains Poor in Spain. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2012, 25, 16-22.	1.4	66

#	ARTICLE	IF	CITATIONS
109	El uso de roflumilast en el tratamiento de la enfermedad pulmonar obstructiva crónica: la perspectiva del neumólogo. Revista De Patología Respiratoria, 2012, 15, 111-122.	0.0	0
110	Fenotipos clínicos de la EPOC. Identificación, definición e implicaciones para las guías de tratamiento. Archivos De Bronconeumología, 2012, 48, 86-98.	0.8	154
111	Validación externa de las recomendaciones del Consenso multidisciplinar sobre Terapia Inhalada. Archivos De Bronconeumología, 2012, 48, 189-196.	0.8	14
112	Guía Española de la EPOC (GesEPOC). Tratamiento farmacológico de la EPOC estable. Archivos De Bronconeumología, 2012, 48, 247-257.	0.8	238
113	Factors Associated With the Control of Severe Asthma. Journal of Asthma, 2010, 47, 124-130.	1.7	57
114	Health-Care Quality Standards in Chronic Obstructive Pulmonary Disease. Archivos De Bronconeumología, 2009, 45, 196-203.	0.8	10
115	Validation of the spanish version of the asthma control questionnaire. Clinical Therapeutics, 2008, 30, 1918-1931.	2.5	43
116	Exacerbations, Hospital Admissions and Impaired Health Status in Chronic Obstructive Pulmonary Disease. Quality of Life Research, 2006, 15, 471-480.	3.1	63
117	Unidades de cuidados respiratorios intermedios. Definición y características. Archivos De Bronconeumología, 2005, 41, 505-512.	0.8	47
118	Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax, 2004, 59, 387-395.	5.6	474
119	Neumonías de lenta resolución. Revista Clinica Espanola, 2004, 204, 375-378.	0.6	1
120	Speed of Recovery from Acute Exacerbations of Chronic Obstructive Pulmonary Disease after Treatment with Antimicrobials. Clinical Drug Investigation, 2003, 23, 439-450.	2.2	33
121	Bronquiectasias. Medicine, 2002, 8, 4121-4126.	0.0	0
122	Treatment and quality of life in patients with chronic obstructive pulmonary disease. Quality of Life Research, 2002, 11, 329-338.	3.1	41
123	ABPA mimicking bronchogenic cancer. Allergy: European Journal of Allergy and Clinical Immunology, 2001, 56, 80-81.	5.7	30